non prescription semaglutide Novo Nordisk to protect US patients from unlawful sales of non-FDA approved 'semaglutide medicines' Semaglutide: Side effects, use for

Tirzepatide SURMOUNT-1 (2022) and SURPASS-2 (2021) SURMOUNT-1 (Jastreboff et al., NEJM 2022): 2,539 non-diabetic adults with BMI 30, 72 weeks of tirzepatide 15 mg/week: Weight loss: 20.9% (vs 3.1% placebo) 91% of participants 5% loss, 56.7% 20% SURPASS-2 (Fras et al., NEJM 2021): 1,879 T2D patients head-to-head vs semaglutide 1 mg: HbA1c: 2.30% (tirzepatide 15 mg) vs 1.86% (semaglutide) Weight loss: 11.2 kg vs 5.7 kg Tirzepatide statistically outperforms semaglutide on both HbA1c and weight in a head-to-head trial a rare outcome in incretin pharmacology

Worch, E

If discomfort occurs at the injection site, a cold compress or gentle massage may help

Chat to your GP

[DOI] [PubMed] [Google Scholar] 46.Shi L., et al